Objectives To determine the effectiveness of ranitidine and sucralfate in the prevention of stress ulcer in critical patients and to assess if these treatments affect the risk of nosocomial pneumonia. Design Published studies retrieved through Medline and other databases. Five meta-analyses evaluated effectiveness in terms of bleeding rates (A: ranitidine v placebo; B: sucralfate v placebo) and infectious complications in terms of incidence of nosocomial pneumonia (C: ranitidine v placebo; D: sucralfate v placebo; E: ranitidine v sucralfate). Trial quality was determined with an empirical ad hoc procedure. Main outcome measures Rates of clinically important gastrointestinal bleeding and nosocomial pneumonia (compared between the two study arms and expressed with odds ratios specific for individual studies and meta-analytic summary odds ratios). Results Meta-analysis A (five studies) comprised 398 patients; meta-analysis C (three studies) comprised 311 patients; meta-analysis D (two studies) comprised 226 patients: and meta-analysis E (eight studies) comprised 1825 patients. Meta-analysis B was not carried out as the literature search selected only one clinical trial. In meta-analysis A ranitidine was found to have the same effectiveness as placebo (odds ratio of bleeding 0.72, 95% confidence interval 0.30 to 1.70, P = 0.46). In placebo controlled studies (meta-analyses C and D) ranitidine and sucralfate had no influence on the incidence of nosocomial pneumonia. In comparison with sucralfate, ranitidine significantly increased the incidence of nosocomial pneumonia (meta-analysis E: 1.35, 1.07 to 1.70, P = 0.012). The mean quality score in the four analyses (on a 0 to 10 scale) ranged from 5.6 in meta-analysis E to 6.6 in meta-analysis A. Conclusions Ranitidine is ineffective in the prevention of gastrointestinal bleeding in patients in intensive care and might increase the risk of pneumonia. Studies on sucralfate do not provide conclusive results. These findings are based on small numbers of patients, and firm conclusions cannot presently be proposed.
Introduction
Ranitidine and sucralfate are widely used to prevent stress ulcers in patients admitted to intensive care units.
1 A meta-analysis published by Cook et al in 1996 showed that H 2 receptor antagonists (such as cimetidine and ranitidine together) are more effective than placebo for this clinical indication.
2 With regard to sucralfate, this meta-analysis found a small but significant reduction in overt bleeding but no effect on clinically important events. The meta-analysis did not resolve the question of an increased risk of nosocomial pneumonia related to the use of H 2 receptor antagonists.
Several arguments emphasise the need for up to date information on this issue. Firstly, ranitidine has become the main H 2 receptor antagonist used for prophylaxis for stress ulcers, and cimetidine has generally been abandoned 1 ; secondly, new findings have been published on effectiveness and complications of ranitidine; and, thirdly, a meta-analytic comparison of ranitidine versus placebo has never been carried out, and as the comparison of sucralfate and placebo made by Cook et al gave no proof of the effectiveness of this drug, ranitidine and sucralfate might both be ineffective. Another problem is that the most recent randomised studies on this topic did not include a group with no prophylaxis and compared supposedly active treatments with one another. 3 4 We conducted a literature search to identify randomised trials, and we carried out a meta-analysis to update the results of Cook's study with regard to effectiveness and infectious complications.
Methods

Searching
Our Medline search covered the period from 1966 to 20 June 2000 and was based on four key words (stress, pneumonia, ranitidine, sucralfate) and on the extraction of studies published in English (see appendix). Randomised studies were identified by using the key words "randomized controlled trial" or "random" according to a validated literature search. 5 This search was supplemented by examining the Iowa-IDIS system ( 
Selection
On the basis of the material produced by our search, we carried out five meta-analyses that evaluated data on effectiveness in terms of rates of bleeding (meta-analysis A: ranitidine v placebo; meta-analysis B: sucralfate v placebo) and data of infectious complications in terms of incidence of nosocomial pneumonia (meta-analysis C: ranitidine v placebo; meta-analysis D: sucralfate v placebo; meta-analysis E: ranitidine v sucralfate). We investigated the issue of effectiveness only in studies with a control group that received no prophylaxis, while the issue of infectious complications was also assessed from comparative trials of ranitidine versus sucralfate. Eligible studies were included in meta-analysis A or B if they met the following criteria: patients were admitted to an intensive care unit or were undergoing mechanical ventilation, or both; randomised design; assessment of gastrointestinal bleeding. We excluded studies in which gastrointestinal bleeding did not meet the definition of "clinically important bleeding" according to Cook et al. 2 In metaanalyses C, D, and E the inclusion criterion gastrointestinal bleeding was replaced by the assessment of pneumonia. The definitions of pneumonia adopted by the individual investigators were recorded but were not assumed to be an inclusion or exclusion criterion.
Data extraction
Data were extracted by one reviewer (MV) with a structured form and checked for accuracy by a second reviewer (ST). Differences were resolved by consensus.
Assessment of quality of trials
We assessed methodological quality of the trials using a procedure similar to that adopted by Cook et al.
2 Five items were evaluated for each trial (patient selection, patient characteristics, randomisation, blinding, definition of bleeding or of pneumonia). Methodological quality was graded for each of the five items on a scale of 0, 1, or 2 (maximum score = 10). Three observers independently assessed quality (AM, MV, MG). Differences were resolved by consensus.
Qualitative data synthesis
Descriptive data for each trial included characteristics of participants, details of intervention, and definition of outcomes. Our assessment of clinical heterogeneity was focused in particular on a comparison of the definitions of bleeding and pneumonia across the trials.
Quantitative data synthesis
With regard to the two end points, the odds ratio was used as the principal measure for comparing the treatment effect within each trial. The results specific for trials were combined through standard meta-analytic techniques [6] [7] [8] to produce the summary odds ratio together with an assessment of the statistical intertrial heterogeneity. The meta-analysis calculations were based both on a fixed effect model 6 7 and on a random effect model. 6 8 The 95% confidence intervals for the odds ratio of individual studies were computed according to Wolf 9 (or by the "rule of three" 10 when zeros were present). To avoid the problems of bias and instability associated with estimation of odds ratios, 0.5 was added to each cell of the fourfold tables in keeping with Cook et al. Heterogeneity was assessed as previously described.
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Results Table 1 shows the trial flow for the five meta-analyses. There were 398 patients in meta-analysis A (five studies), 54 in meta-analysis B (one study), 311 in meta-analysis C (three studies), 226 in meta-analysis D (two studies), and 1825 in meta-analysis E (eight studies). Table 2 shows descriptive data for all the trials included in our meta-analyses.
Effectiveness of ranitidine v placebo (meta-analysis A)-Our literature search identified five trials, [11] [12] [13] [14] [15] three of which had already been included by Cook et al. [11] [12] [13] The mean (SD) quality score for these trials was 6.6 (0.9). With respect to the end point of clinically important bleeding, this meta-analysis (table 3) failed to show any significant benefit of ranitidine (summary odds ratio 0.72, 95% confidence interval 0.30 to 1.70, P = 0.46 for fixed effect model; 0.95, 0.37 to 2.43, P = 0.92 for random effect model; 2 for heterogeneity 6.8, df 4, P = 0.15).
Effectiveness of sucralfate v placebo (meta-analysis B)-Our literature search found the same randomised trials that had already been examined by Cook et al (three trials [16] [17] [18] for the end point of overt bleeding and one trial 11 for the end point of clinically important gastrointestinal bleeding). Because our analysis considered the end point of clinically important bleeding, only one trial 11 met the inclusion criteria and so no meta-analysis was carried out. The quality score of the trial of Ruiz-Santana et al was 7.0. The results of the study by Cook et al remained unchanged (table 4) with no difference between sucralfate and placebo (1.26, 0.12 to 12.9, P = 0.70). *Studies were excluded because they did not compare treatment options considered by meta-analysis in question (A=16; B=18, C=12; D=14; E=1) or because objective of trial was not prophylaxis of stress ulcer (A=29; B=23, C=44; D=19; E=1) or because they duplicated study already included in meta-analysis question (A=0; B=1, C=0; D=0; E=1). †Studies excluded because end point of bleeding did not meet definition of "clinically important bleeding" according to Cook et al.
Incidence of pneumonia with ranitidine v placebo (metaanalysis C)-
Our third meta-analysis included three randomised studies 12 13 15 that compared the incidence of pneumonia between ranitidine and placebo (two of these trials 12 13 had already been included in the metaanalysis by Cook et al). The mean (SD) quality score for these trials was 6.0 (1.0). The analysis of these three trials (table 5) found no significant difference in the rate of pneumonia with ranitidine and placebo (summary odds ratio 0.98, 0.56 to 1.72, P = 0.94 for fixed effect model; 1.10, 0.45 to 2.66, P = 0.84 for random effect model; 2 for heterogeneity 4.38, df 2, P = 0.11).
Incidence of pneumonia with sucralfate v placebo (metaanalysis D)-Our fourth meta-analysis included two randomised studies 17 18 that compared the incidence of pneumonia between sucralfate and placebo (both trials had already been included in the meta-analysis by Cook et al). The quality score for these trials was 6.0 (1.4). The analysis of these two trials (table 6) found no significant difference in the rate of pneumonia with sucralfate and placebo (summary odds ratio 2.21, 0.86 to 5.65, P = 0.10 for fixed effect model; 2.11, 0.79 to 5.64, P = 0.14 for random effect model; 2 for heterogeneity 0.30, df 1, P = 0.58).
Incidence of pneumonia with ranitidine v sucralfate (meta-analysis E)-Our fifth meta-analysis included eight randomised studies 3 19-26 that compared the incidence of pneumonia with ranitidine and sucralfate (five of these trials [19] [20] [21] [22] [23] had already been included in the *In assessment of blinding we assigned score of 1 to single blind studies in which outcome assessor was blind and both caregiver and patient were unblind. †Median. ‡Population studied in effectiveness analysis (n=167) differed from that included in analysis on pneumonia (n=163) because four patients had pneumonia at baseline.
§Results of this clinical trial have in part been reported previously.
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meta-analysis by Cook et al). The quality score for these trials was 5.6 (2.3). The analysis of these eight trials (table 7) showed a significantly increased risk of pneumonia with ranitidine compared with sucralfate (summary odds ratio 1.35, 1.07 to 1.70, P = 0.012 for fixed effect model; 1.51, 1.00 to 2.29, P = 0.05 for random effect model; 2 for heterogeneity 12.9, df 7, P = 0.08).
Discussion
Our overview of the controlled trials of ranitidine or sucralfate compared with placebo provides a picture of poor effectiveness. The single trial available on sucralfate 11 does not allow any conclusion to be drawn; the trials on ranitidine [11] [12] [13] [14] [15] show no difference compared with placebo.
Our results on ranitidine need to be compared with those previously published by Cook et al. 2 In their assessment of effectiveness of H 2 receptor antagonists Cook et al included five trials that used cimetidine [29] [30] [31] [32] [33] and three trials with negative results that used ranitidine [11] [12] [13] (plus one trial on ranitidine published in Spanish 34 and one trial with negative results that used a combination of ranitidine and antacids, 35 both of which did not meet the criteria for our meta-analysis). Cimetidine is probably effective at statistical levels, as out of the trials that used cimetidine three had positive results, one had significant results in patients at low (table 8) showed a significant reduction in bleeding (with P < 0.001 and P < 0.01 according to the fixed effect and the random effect models, respectively). Can we accept the hypothesis that cimetidine is effective and ranitidine is ineffective? Is this hypothesis pharmacologically plausible? Our separate analyses for individual drugs did not actually settle the entire question. In fact, the cohorts included in the studies that used these two drugs were small and the incidence of events was low, particularly in the case of ranitidine (10 cases of bleeding with the drug v 15 without prophylaxis; table 3); so the different results might reflect casual variations in the outcome rather than a true difference between the two H 2 receptor antagonists. Another point of uncertainty about cimetidine is the methodological quality of studies published many years ago.
Design of new trials
Our results indicate that some points of consensus need to be revised. For example, recent randomised studies on prophylaxis for stress ulcers 3 4 have invariably compared (unproved) active treatments with one another but no longer use a placebo group, and authoritative recommendations suggest the use of ranitidine for prophylaxis for stress ulcers. 36 New large scale randomised trials seem to be the only way to resolve this issue. New trials, however, may raise the ethical question of which treatment is appropriate for the control group. One possibility is to give cimetidine to the control group, but this solution raises the question of reusing a drug that has largely been abandoned. Another possibility is to conduct new large scale controlled trials of ranitidine compared with placebo, but the use of placebo can be questionable from an ethical point of view. A third solution could be to design new randomised trials according to a strategy of early treatment of stress ulcer with or without prophylaxis. In this latter case, after randomisation to prophylaxis or placebo the patients could be subjected to intensive gastrointestinal monitoring (for example, by examining nasogastric aspirate at short intervals) and, at the first signs of bleeding, their participation in the trial could be stopped with immediate initiation of an aggressive antisecretory treatment. A drawback of this third solution is that the clinical weight of the end point of early bleeding is less than that of the end point of clinically important bleeding.
Effect on pneumonia
The results of three meta-analyses that evaluated pneumonia were contradictory in some respects (ranitidine v placebo and sucralfate v placebo had the same incidence of pneumonia; for ranitidine v sucralfate there was a significantly higher incidence of pneumonia with ranitidine, P = 0.012).The statistical power of these comparisons was better for meta-analysis E (1825 patients) than for meta-analysis C (311 patients); this could in part explain the higher incidence of pneumonia with ranitidine compared with sucralfate but not compared with placebo. The large trial by Cook et al showed a trend towards an increased incidence of pneumonia with ranitidine v sucralfate (definite pneumonia associated with use of ventilator and pneumonia according to the definition of the Centers for Disease Control and Prevention was more common with ranitidine, at P = 0.03 and P = 0.13, respectively).
3 Discrepancies between large trials and meta-analysis have been pointed out in cases where the meta-analysis was conducted before the large trial. 37 In our study, however, the metaanalysis on pneumonia already included the large trial and, more importantly, its results did not differ much from those of the large trial (odds ratio of 1.35 v 1.18, respectively).
These arguments related to statistical power and agreement between large scale trials and meta-analyses do not, however, exclude the other explanation that the increase in rates of pneumonia after ranitidine was simply the result of casual variations in the outcome. In this context, the repeated application of statistical testing to many data sets might have contributed to the generation of some significant results.
Our main conclusion is that there are insufficient data on effectiveness to be able to conclude anything one way or the other. This can be an important argument for further trials.
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